Rehmann Capital Advisory Group Has $19 Million Stock Position in Stryker Corporation $SYK

Key Points

• Rehmann Capital Advisory Group reduced its Stryker position by 5% in the second quarter, selling 3,191 shares and retaining 60,357 shares valued at approximately $19.0 million.
• Institutional investors own 77.09% of Stryker, while insiders have sold approximately $118.2 million worth of shares over the past three months.
• Stryker exceeded quarterly earnings expectations, reporting $3.69 in EPS and $6.59 billion in revenue, up 9.4% year over year. The company also declared a quarterly dividend of $0.88, representing a 1.1% annualized yield.

Rehmann Capital Advisory Group cut its position in Stryker Corporation (NYSE:SYK - Free Report) by 5.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,357 shares of the medical technology company's stock after selling 3,191 shares during the period. Stryker accounts for approximately 0.8% of Rehmann Capital Advisory Group's investment portfolio, making the stock its 22nd biggest holding. Rehmann Capital Advisory Group's holdings in Stryker were worth $19,003,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Norges Bank acquired a new stake in Stryker in the fourth quarter valued at approximately $1,822,272,000. Bank of America Corp DE acquired a new position in shares of Stryker during the second quarter worth approximately $1,404,284,000. Auto Owners Insurance Co lifted its holdings in shares of Stryker by 35,047.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company's stock worth $1,024,444,000 after purchasing an additional 2,906,448 shares in the last quarter. Legal & General Group Plc acquired a new stake in Stryker in the 2nd quarter valued at $707,212,000. Finally, Jupiter Topco LLC bought a new stake in Stryker during the 2nd quarter valued at $681,581,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 50,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the transaction, the director directly owned 2,251,375 shares of the company's stock, valued at approximately $765,692,637.50. This trade represents a 2.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Dylan Bram Crotty sold 441 shares of the business's stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. The trade was a 6.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 351,267 shares of company stock valued at $118,197,701 over the last three months. 4.60% of the stock is currently owned by insiders.

Stryker Stock Performance

NYSE SYK opened at $324.32 on Tuesday. The company has a market capitalization of $124.40 billion, a PE ratio of 33.61, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company has a 50-day simple moving average of $329.49 and a 200 day simple moving average of $331.03.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker's dividend payout ratio (DPR) is 36.48%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Barclays dropped their target price on Stryker from $469.00 to $394.00 and set an "overweight" rating on the stock in a report on Monday, May 4th. JPMorgan Chase & Co. reduced their target price on shares of Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a research note on Friday, July 31st. BTIG Research dropped their price target on shares of Stryker from $371.00 to $358.00 and set a "buy" rating on the stock in a research report on Friday, July 31st. Wolfe Research cut shares of Stryker from an "outperform" rating to a "peer perform" rating in a report on Thursday, August 13th. Finally, Citigroup reiterated a "buy" rating on shares of Stryker in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source